CSIMarket
 
Generation Bio Co   (GBIO)
Other Ticker:  
 
 
Price: $3.0900 $0.12 4.040%
Day's High: $3.12 Week Perf: -3.44 %
Day's Low: $ 2.86 30 Day Perf: 57.65 %
Volume (M): 481 52 Wk High: $ 6.98
Volume (M$): $ 1,485 52 Wk Avg: $3.41
Open: $2.93 52 Wk Low: $0.86



 Market Capitalization (Millions $) 200
 Shares Outstanding (Millions) 65
 Employees 174
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -127
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 7

Generation Bio Co
Generation Bio Co is a biotechnology company that is dedicated to developing cutting-edge gene therapy treatments for rare genetic diseases. The company was founded in 2016 by a team of experienced scientists from top institutions like Harvard Medical School, MIT, and the Broad Institute.

The central focus of Generation Bio Co's work is to create gene therapies that utilize adeno-associated viruses (AAV) as vectors to deliver genetic payloads to specific cells in the body. This approach allows for the correction or replacement of defective genes, which is essential for the treatment of countless inherited disorders.

One of the key innovations that sets Generation Bio Co apart is its robust and versatile genetic engineering platform. This platform incorporates various techniques like directed evolution, DNA shuffling, and high-throughput screening to create novel AAV vectors that are highly effective at delivering therapeutic genes to target cells.

The company's founders have a deep commitment to pursuing safe and effective gene therapies. As such, they have developed rigorous safety protocols and are following strict guidelines set by the FDA for clinical trials. Generation Bio Co also emphasizes transparency, ethics, and the involvement of patients and families in the development process.

Currently, Generation Bio Co is working on several promising gene therapy programs across a range of genetic diseases, including hemophilia, phenylketonuria, and spinal muscular atrophy. These therapies have shown impressive results in preclinical studies and are poised to move into clinical trials in the near future.

In summary, Generation Bio Co is a biotechnology company that is focused on developing advanced gene therapies for the treatment of rare genetic diseases. The company is driven by a talented team of scientists who employ innovative technologies to create effective and safe genetic therapies. With a robust pipeline of promising therapies, Generation Bio Co is poised to make a significant impact on the field of gene therapy and the lives of millions of people around the world.


   Company Address: 301 Binney Street Cambridge 2142 MA
   Company Phone Number: 655-7500   Stock Exchange / Ticker: NASDAQ GBIO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Generation Bio Co

Generation Bio Co Boasts Quarter 4 Revenue of $2.878 Million- Stay Informed on the Latest Earnings Results

The stock market is always filled with ups and downs, and it is crucial for investors to stay updated with the latest developments. In recent news, the Major Pharmaceutical Preparations company has showcased promising results in the fourth quarter of 2023. With a revenue of $2.878 million, the company has successfully demonstrated its ability to generate substantial income.
Additionally, Generation Bio Co, a significant player in the industry, reported a net loss of $-35.186 million for the same quarter. Although this figure is higher than the previous year's loss of $-32.405 million, it is essential to consider the context. The build-up in accounts receivable suggests a rising demand, indicating positive growth in the market.

Generation Bio Co

Generation Bio Co. Achieves Outstanding Revenue of $2.146 Million in Q3 of Fiscal Year 2023

Generation Bio Co, a leading biotechnology company, has recently announced its financial results for the third quarter of the 2023 earnings season. The company reported a revenue of $2.146 million during this period, showcasing its strong market presence and positive performance.
However, it is important to note that Generation Bio Co also reported a net deficit of $-28.266 million in the third quarter of 2023 earnings season. Although this may seem concerning, it is worth mentioning that this deficit is actually an improvement compared to the deficit of $-31.306 million in the same reporting period last year. This indicates that the company has been able to reduce its losses and move towards a more stable financial position.

Generation Bio Co

Generation Bio Co Reports $0.88 Million Revenue for Recent Fiscal Period Ending June 2023

Financial News Report:
In the fiscal span ending June 30, 2023, the Major Pharmaceutical Preparations company reported a revenue of $0.88 million. This indicates a steady performance in terms of revenue generation for the company.
On the other hand, Generation Bio Co, a pharmaceutical company, reported a net loss of $-31.066 million, which is an improvement compared to the same reporting period a year ago when they had a deficit of $-37.929 million. This suggests that the company is making progress in managing their financials and reducing their losses.

Generation Bio Co

Promising Growth: Generation Bio Co Reportedly Reduces Operating Deficit in First Quarter Fiscal 2023

Generation Bio Co is a biotechnology company that is currently gaining momentum in the pharmaceutical sector. The company is dedicated to developing cutting-edge genetic therapies that can revolutionize the way diseases are treated and cured. Although the company has yet to generate any revenue, shareholders are closely monitoring the company's progress as evidenced by its recent financial reports.
During the first quarter of 2023, Generation Bio Co's operating deficit came in at $-34.866 million, which has improved from the same period last year. The company has been able to mitigate some of its losses, as the diminishing returns have been trimmed from the period one year ago. This is a positive development that signals a bright future for the company.






 

Generation Bio Co's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Generation Bio Co does not provide revenue guidance.

Earnings Outlook
Generation Bio Co does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com